ERBB2 and breast cancer: Furthermore, the addition of Trastuzumab for one year to CT with anthracycline and/or taxane has dramatically changed the natural history of BC HER2 neu + as shown by four randomized adjuvant studies, such as HERA, NSABP B-31, NCCTG N9831 and BCIRG 006.